Phesgo and Tecentriq Performance and Approvals

Q1 2023: Group sales decline driven by COVID-19 sales erosion Pharmaceuticals Division Diagnostics Division Roche Group 2023 2022 Change in % Excl. CHFbn CHFbn CHF CER C191 11.7 11.2 5 9 9 3.6 5.3 -31 -28 4 15.3 16.4 -7 -3 8 CER-Constant Exchange Rates; totals may include differences due to rounding; 1 Pharmaceuticals Division sales excluding Ronapreve, Diagnostics Division base business Roche 7

View entire presentation